| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f2f698cea2f100daf2cd716370e6244 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbd50172713f505bb18c9e7501d82ddd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d717ba61e4264d1726392a14bad7b661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f282bf204a641a7a19d310e8b015dff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b88bb93500f1462e22137692a335f6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25bb09475a32bfe9ef289c5e38d954ef |
| publicationDate |
2011-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011123549-A1 |
| titleOfInvention |
Antibodies to EphA3 |
| abstract |
The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9109032-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021092560-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013025467-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011123819-A3 |
| priorityDate |
2009-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |